1 Viridian Therapeutics Inc Receivables Turnover Ratio (VRDN), from the first quarter 2026 to the first quarter 2024 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Viridian Therapeutics Inc   (NASDAQ: VRDN)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

Viridian Therapeutics Inc Accounts Receivables Turnover Ratio from the first quarter 2026 to the first quarter 2024

Quarterly Results, Trends, Rankings, Statistics


According to Viridian Therapeutics Inc Balance Sheet, in the first quarter 2026, company has not reported any Accounts receivable.
See Viridian Therapeutics Inc Balance Sheet

If we take a look into Healthcare sector 450 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2921, from overall ranking in the fourth quarter 2025 at 2922.

What is Receivable Turnover Ratio?
What is Viridian Therapeutics Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRDN Receivables Turnover Ratio (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Receivable Change - - - - -
Y / Y Revenue Change 95.83 % 40.7 % 97913.89 % 0 % 0 %
Receivable Turnover Ratio (TTM) - - - - -
VRDN's Total Ranking # 2921 # 2922 # 2957 # 3777 #
Accounts Receivable average collection period days - - - - -
Seq. Receivable Change - - - - -
Seq. Revenue Change 16.53 % -99.83 % 97913.89 % 0 % -16.28 %


Receivable Turnover Company Ranking
Within: No.
Medical Laboratories Industry # 29
Healthcare Sector # 451
Overall Market # 2921

Receivable Turnover Ratio Statistics
High Average Low
0.1 0.02 0
(Sep 30 2025)   (Mar 31 2025)





VRDN Company Profile • Back to VRDN Efficiency Comparisons • Compare VRDN Receivables Turnover Ratio to its Competitors

Financial Statements
Viridian Therapeutics Inc 's Accounts Receivable $ 0 Millions Visit VRDN's Balance sheet
Viridian Therapeutics Inc 's Sales TTM $ 71 Millions Visit VRDN's Income Statement
Sources of VRDN's Revenues Visit VRDN's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Laboratories Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
VRDN's Receivable Turnover Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
VRDN's Growth Rates VRDN's Roa VRDN's Inventory Turnover Ratio VRDN's Dividend Comparisons
VRDN's Profitability Ratios VRDN's Roi VRDN's Asset Turnover Ratio VRDN's Dividend Growth
VRDN's Valuation Ratios VRDN's Roe VRDN's Financial Strength Ratios VRDN's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Mar 31 2026 Receivable at quarter ending Mar 31 2026

Date modified: 2026-08-29T17:24:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.